Orpyx Medical Technologies, a Calgary, Canada-based developer of digital health therapeutics to prevent diabetic foot complications, closed a $7.6M Series A funding round.
The round, which brought total funding since inception to $18.5M, was led by Paddock Capital with participation from existing and new investors, including Aphelion Capital, Thin Air Labs, InterGen Capital, Relentless Venture Fund, ICM Asset Management, Anges Québec, Picante Capital Corp. and Viewpoint Group. In conjunction with the funding, Cory Paddock, co-founder and Managing Director of Paddock Capital Inc, will join the Board of Directors.
The company intends to use the funds to expand its North American commercialization efforts as well as broaden and accelerate technology development.
Led by Dr. Breanne Everett, CEO and co-inventor, Orpyx provides Orpyx® SI Sensory Insoles, a sensory insole with telemedicine capabilities that provides patients and their healthcare provider real-world feedback to help prevent diabetic foot and other neuropathy-related ulcers through advanced foot sensor technology and real-time analytics. The technology is also used by researchers to access clinical-grade plantar pressure data for health and human performance applications in the fields of sports medicine, therapeutic applications, and footwear design.